VIR News and Press, Vir Biotechnology Inc. From 12/13/23

– Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology – – Reducing workforce by approximately 12% and consolidating geographic footprint...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42 nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of t...

2023-11-30 06:10:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks to buy offer a window into the future of the global economy, encapsulating companies with market capitalizations upwards of $250 million and $2.5 billion. These are the pot...

– Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy – – New MARCH Part B data demonstrate that VIR-3434 may play an important role in achieving a functional cure for chronic h...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for...

2023-11-08 11:27:49 ET Summary VIR took a big hit in July with the failure of the company's trial in influenza, but the stock has continued to slide since. A new BARDA contract to develop a COVID antibody and another drug against a pathogen with pandemic potential has failed to li...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500 ™ , a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This i...

2023-11-04 12:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. We highlight October investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come...

2023-11-03 16:46:43 ET More on Vir Biotechnology Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further Clarity Vir Biotechnology GAAP EPS of -$1.22 beats by $0.03, revenue of $2.6M misses by $6.17M For further details see: Vir Biotechnolo...

2023-11-03 15:00:40 ET More on the markets SPY: From Bullish To Bearish - Why The Bears Could Be Right This Time (Rating Downgrade) My View Of The S&P 500 November 2023 Edition (Technical Analysis) Famous Chart Pattern Returns To Life Six bullish stocks t...